Tag: Mavacamten

Explore our medication guides and pharmacology articles within this category.

What is the new medication for hypertrophic cardiomyopathy?

Oct 11, 2025 •

4 min read

Hypertrophic cardiomyopathy (HCM) affects an estimated 1 in 500 people, though some genetic data suggests the prevalence could be as high as 1 in 200 [1.5.4, 1.8.5]. Historically, treatments only managed symptoms. So, *what is the new medication for hypertrophic cardiomyopathy* that offers a targeted approach?

Mavacamten: What is the new drug for hypertrophic cardiomyopathy?

Oct 11, 2025 •

3 min read

Affecting approximately 1 in 500 people, hypertrophic cardiomyopathy (HCM) is a genetic heart condition that causes the heart muscle to thicken. Mavacamten (brand name Camzyos) is the new drug for hypertrophic cardiomyopathy, specifically for the obstructive type (oHCM).